H.R. 679 (119th)Congressional Activities
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Health|AbortionDrug safety, medical device, and laboratory regulation
Current stageCommittee
Referred to the House Committee on Energy and Commerce.
Introduced
Committee
Floor
President
Law
Congressional Activities
This tab collects committee work, CRS research, hearings, and amendment activity as those sources become available for the bill.
No congressional activity records are linked to this bill yet.